In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Pfizer, Neurocrine end agreement for indiplon

Executive Summary

Neurocrine Biosciences (neurological therapeutics) and Pfizer have entered into an agreement for the development and marketing of Neurocrine's insomnia compound indiplon (also referred to as NBI-34060). Neurocrine received its right to indiplon under a 1998 sub-license agreement with Dov Pharmaceuticals; Dov had licensed it shortly before, from Wyeth.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Contract
    • Includes Royalty or Profit Split Information
    • Product or Technology Swap
    • R&D and Marketing (Licensing)

Related Companies